Gemini DRC A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103